The influence of probiotics to the efficacy of 5-ASA for the patients of ulcerative colitis

被引：0
|
作者：
Yasuda, R. [1 ]
Uchiyama, K. [1 ]
Takagi, T. [1 ]
Kubota, M. [1 ]
Sugino, S. [1 ]
Azuma, Y. [1 ]
Kitae, H. [1 ]
Torii, T. [1 ]
Takayama, S. [1 ]
Inoue, K. [1 ]
Katada, K. [1 ]
Kamada, K. [1 ]
Ishikawa, T. [1 ]
Konishi, H. [1 ]
Naito, Y. [1 ]
Itoh, Y. [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Gastroenterol & Hepatol, Kyoto, Japan
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P710
引用
收藏
页码：S573 / S573
页数：1
相关论文
共 50 条
  • [41] Dose finding study of the efficacy and safety of newly developed 5-ASA containing pellets in patients with active ulcerative colitis.
    Kruis, W
    Bar Meir, S
    Feher, J
    Stolte, M
    Kalk, EK
    GASTROENTEROLOGY, 2000, 118 (04) : A780 - A780
  • [42] OPEN STUDY OF 5-ASA SUPPOSITORIES IN ULCERATIVE PROCTITIS (UP) AND ULCERATIVE-COLITIS (UC)
    SIDOROV, JJ
    WILLIAMS, CN
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1986, 9 (03): : A60 - A60
  • [43] 5-ASA Induced Recurrent Myopericarditis and Cardiac Tamponade in a Patient with Ulcerative Colitis
    Sonu, Irene
    Wong, Robert
    Rothenberg, Michael E.
    DIGESTIVE DISEASES AND SCIENCES, 2013, 58 (08) : 2148 - 2150
  • [44] Efficacy of Oral Mesalamine Monotherapy (5-ASA) versus Combination Oral Mesalamine Plus Proton Pump Inhibitor (5-ASA/PPI) Therapy in the Treatment of Ulcerative Colitis (UC)
    Lichtenstein, Gary
    Marchioni, Renee
    Blonski, Wojciech
    Mudireddy, Prashant
    Buchner, Anna
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S630 - S631
  • [45] Plasma Inflammation-related Proteins Predict the Therapeutic Effect of 5-ASA in Patients with Ulcerative Colitis
    Dang, Y.
    Xu, X.
    Zhou, M.
    Xu, C.
    Huang, X.
    Xu, F.
    Wang, Z.
    Wang, C.
    Zhu, S.
    Li, P.
    Zhang, S.
    Shi, H.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1240 - I1241
  • [46] Combined butyrate/5-ASA therapy is more effective than 5-ASA alone in refractory distal ulcerative colitis. A GISC study
    Vernia, P
    Villotti, G
    Annese, V
    Bresci, G
    D'Albasio, G
    D'Inca, R
    Giaccari, S
    Ingrosso, M
    Mansi, C
    Riegler, G
    Valpiani, D
    Caprilli, R
    GASTROENTEROLOGY, 1999, 116 (04) : A840 - A840
  • [47] Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis
    Takahashi, Fumiaki
    Tominaga, Keiichi
    Kanamori, Akira
    Takenaka, Kazuhiro
    Hoshino, Atsushi
    Sugaya, Takeshi
    Nakano, Masakazu
    Hiraishi, Hideyuki
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2016, 51 (07) : 827 - 834
  • [48] 5-ASA prescription refill rates for ulcerative colitis are independent of formulation and dosing regimens
    Magowan, Simon H.
    Kane, Sunanda
    Lange, Jeffrey L.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S447 - S447
  • [49] 5-ASA ENEMA VERSUS ORAL SULFASALAZINE IN MAINTAINING REMISSION IN ULCERATIVE-COLITIS
    ANDREOLI, A
    SPINELLA, S
    LEVENSTEIN, S
    PRANTERA, C
    ITALIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1994, 26 (03): : 121 - 125
  • [50] Use of 5-ASA is associated with decreased risk of dysplasia and colon cancer in ulcerative colitis
    Rubin, DT
    Djordjevic, A
    Huo, D
    Yadron, N
    Hanauer, SB
    GUT, 2004, 53 : A119 - A119
12345